APPLIED DNA SCIENCES INC. news, videos and press releases
For more news please use our advanced search feature.
APPLIED DNA SCIENCES INC. - More news...
APPLIED DNA SCIENCES INC. - More news...
- Applied DNA Announces 1-For-20 Reverse Stock Split
- Applied DNA Enters into Agreement with Alphazyme for Scale-Up Manufacturing of its Proprietary Linea(TM) RNAP, Progresses Towards GMP Linea(TM) IVT Production Start
- Applied DNA to Showcase Linea(TM) DNA and Linea(TM) IVT Platforms at 24th Annual World Vaccine Congress
- Applied DNA Announces First Quarter Fiscal Year 2024 Financial Results
- Applied DNA to Report First Quarter Fiscal 2024 Financial Results on Thursday, February 8, 2024
- Applied DNA Announces Closing of $3.44 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
- Applied DNA Announces $3.44 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
- Applied DNA Announces Joint Development Agreement to Integrate Linea(TM) IVT Platform into CDMO Kudo Biotechnology’s mRNA Manufacturing Workflow
- Applied DNA Announces Fourth Quarter Fiscal Year 2023 Financial Results
- Long Island Capital Alliance to Hold Cannabis Capital Forum on December 8, 2023
- Applied DNA to Report Fiscal 2023 Fourth Quarter and Year End Financial Results on December 7, 2023
- Applied DNA Announces Receipt of Linea(TM) DNA Follow-On Order for Cancer Diagnostic Application
- Applied DNA Extends Application of Linea(TM) IVT Platform to saRNA (self-amplifying mRNA)
- Applied DNA Ships First saRNA (self-amplifying mRNA) IVT Template Generated by Linea(TM) DNA Platform
- Applied DNA Partners with Cornell University College of Veterinary Medicine to Accelerate Development of Veterinary Vaccine Platform Targeting Diseases that Impact High-Value Animals
- Applied DNA Advances Commercialization of Linea(TM) IVT Platform, Appoints Beverly Wolgast as Executive Director of Quality and cGMP Programs
- Applied DNA Announces Availability and First Customer Shipment of New Linea(TM) IVT Evaluation Kit
- Applied DNA Files Provisional Patent Applications for Methods of Double-Stranded RNA Mitigation in Next-Generation mRNA Production
- Applied DNA Reports Third Quarter Fiscal 2023 Financial Results and Provides Corporate Update
- Applied DNA to Report Third Quarter Fiscal 2023 Financial Results and Host Investor Conference Call and Webcast on Thursday, August 10, 2023
- Applied DNA Biotherapeutics Subsidiary LineaRx to Participate in Upcoming mRNA Industry Conferences
- Applied DNA Acquires RNA Polymerase Developer Spindle Biotech, Launches LineaIVT(TM) Platform to Substantially Improve mRNA Manufacturing and Broaden Market Reach
- Thinking about buying stock in Xpeng, Nio, Applied Optoelectronics Inc, ConforMIS, or Applied DNA Sciences?
- Applied DNA Announces Presentation at Upcoming Healthcare Investor Conference
- Applied DNA Reports Second Quarter Fiscal 2023 Financial Results and Provides Corporate Update
- Applied DNA to Report Second Quarter Fiscal 2023 Financial Results and Host Investor Conference Call and Webcast on Thursday, May 11, 2023
- Applied DNA's CertainT® Supply Chain Traceability Platform Featured in New York Times Article About the Need for Transparency and Compliance in Global Supply Chains Under Recently Passed U.S. Federal Regulation
- Applied DNA Achieves Milestone for Large-Scale linearDNA™ Production, Delivers Largest Single Shipment by Volume to Date
- Applied DNA Submits Validation Package to New York State Department of Health for Approval of Pharmacogenomic (PGx) Assay
- Applied DNA Announces New York State Award Valued at Up To $1.5 Million to Support Establishment of cGMP linearDNA™ Production Capacity on Long Island, New York
